AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04044963 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise and Prehabilitation
Description: All participants who are allocated to the exercise group will be asked to complete 4-5 days per week of mixed modality exercise incorporating aerobic, resistance, and flexibility training. The aerobic component can include any modality the patient is capable of doing, including walking, swimming or biking. By the end of the prehabilitation period the target will be 30 minutes of aerobic exercise three times a week at an intensity of 3-5 RPE. The resistance component will include 5-6 exercises using body weight and resistance bands. The target will be 12 repetitions and 3 sets, two times a week. The flexibility component will include 5 exercises that can be completed at the end of each session.~Participants will self-report their participation in the prehabilitation program based on an electronic survey.
Study NCT04402710 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-compassion
Description: Six week behavioural change program plus a self-compassion intervention aimed to increase physical activity among individuals with prediabetes
Study NCT04402710 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Six week behavioural change program aimed to increase physical activity plus information on general health topics.
Study NCT01977222 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: THRESHOLD(TM) INSPIRATORY MUSCLE TRAINER
Description: Subjects will be provided with noseclips and a threshold impedance device set to 40% of their measured maximal inspiratory pressure and will be trained on using the device. Specifically, subjects will be instructed to breathe through the inspiratory muscle training device while wearing noseclips at a rate of 12 to 16 breaths per minute for 30 minutes a day, 5 days a week for 12 consecutive weeks. Each subject will be provided a customized schedule for increasing resistance by 2 cm H2O every 2 weeks to a maximum resistance of 41 cm H2O.
Study NCT01486303 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Facial Cosmetic Acupuncture
Description: Patients received five treatment sessions during 3 weeks. Facial cosmetic acupuncture was applied at muscles and acupoints on the face, head and neck
Study NCT02042339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen
Description: The treatment will be applied in a large walk-in drive-in hyperbaric chamber. Depending on their general condition, the patients will sit in comfortable chairs or remain in their own wheelchair or bed in relaxed position. They will be accompanied by a medical attendant or by a hyperbaric physician if necessary due to their general condition. Oxygen 100% will be distributed over a tight fitting oxygen-mask connected to the overboard-dumping system. The treatment will be administered according to the so-called problem-wound schedule once a day for six consecutive weeks. On weekends and on public holidays the patients will be off therapy.
Study NCT02042339 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hyperbaric oxygen
Description: The treatment will be applied in a large walk-in drive-in hyperbaric chamber. Depending on their general condition, the patients will sit in comfortable chairs or remain in their own wheelchair or bed in relaxed position. They will be accompanied by a medical attendant or by a hyperbaric physician if necessary due to their general condition. Oxygen 100% will be distributed over a tight fitting oxygen-mask connected to the overboard-dumping system. The treatment will be administered according to the so-called problem-wound schedule once a day for six consecutive weeks. On weekends and on public holidays the patients will be off therapy.
Study NCT02742441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 122-0551 Foam
Description: Topical Foam containing active drug
Study NCT02300896 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group-based exercise training during hospitalization
Description: Exercise training. Individual program training 5 days a week during hospitalization
Study NCT02723136 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smartphone Application
Description: Smartphone application developed by internists and engineers. Will be made available on iOS(R) and Android(R) operating systems.
Study NCT02943512 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Discharge day of procedure
Description: Subjects will be discharged the day of the procedure if safe
Study NCT00615251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DR-2011
Description: Progesterone vaginal ring for approximately 10 weeks
Study NCT00615251 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Crinone 8%
Description: progesterone vaginal gel for approximately 10 weeks
Study NCT00379262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Dose:1000 mg/m2, BD, Day 1-Day 14 Interval: 21 days Cycles: 3 cycles
Study NCT00379262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy using PF (5-Fluorouracil )
Description: Cisplatin 80 mg/m2 IV + 5-Fluorouracil 1000 mg/m2/day IV infusion for 96 hr every 28 days for 3 cycles
Study NCT00379262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy using PF (5-Fluorouracil)
Description: Cisplatin 100 mg/m2 IV + 5-Fluorouracil 1000 mg/m2/day IV infusion for 120 hr every 21 days for 3 cycles
Study NCT01908517 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HPV Vaccine Electronic Reminders
Description: The intervention group will receive 4 education messages, 2 reminder/education messages, as well as 1 baseline and 1 final assessment survey. Control group participants will receive 2 contacts throughout the study, 1 at baseline and 1 at their final assessment survey. Up to two reminder contacts will be used if surveys are not completed for both intervention and control group participants. Preference for receipt of reminders will be obtained from the information study card parents complete at study enrollment. Enrollment card content, educational messages and patient- reminders will all be developed with community input.
Study NCT02561299 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Peripheral Orbital Atherectomy System
Description: Orbital Atherectomy
Study NCT02561299 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 014 Drug Coated Balloon
Description: Drug Coated Balloon
Study NCT02561299 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 014 Drug Coated Balloon
Description: Drug Coated Balloon
Study NCT03827590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test
Description: three times a day for five days
Study NCT00687167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zonisamide 100 mg Capsule
Description: 100 mg capsule administered 30 minutes after initiation of standardized, high-fat breakfast.
Study NCT00687167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zonisamide (Zonegran®) 100 mg Capsule
Description: 100 mg capsule administered 30 minutes after initiation of standardized, high-fat breakfast.
Study NCT02382328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alpha lipoic acid
Description: comparison of 600mg/24h oral, alpha lipoid acid, 28 days before and 120 days after surgery (carpal tunnel release) versus placebo in carpal tunnel syndrome patients.
Study NCT02382328 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral pills, 28 days before and 120 days after surgery (carpal tunnel release) versus placebo in carpal tunnel syndrome patients.
Study NCT01176110 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LMA Perfect Temp
Description: The LMA PerfecTemp™ patient warming system combines warming beneath the patient and advanced pressure reduction to combat hypothermia and decubitus ulcers. This device is used during the interventional minimal invasive valve replacement with unprecedented ease and safety
Study NCT01176110 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LMA Perfect Temp
Description: The LMA PerfecTemp™ patient warming system combines warming beneath the patient and advanced pressure reduction to combat hypothermia and decubitus ulcers. This device is used during the interventional minimal invasive valve replacement with unprecedented ease and safety
Study NCT02225665 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: SB-728mR-T
Description: -SB-728mR-T infusions of 2 equal doses 14 days apart (total of up to 40 billion ZFN modified T-cells)
Study NCT02225665 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: SB-728mR-T
Description: - SB-728mR-T infusions of 3 equal doses 14 days apart (total of up to 40 billion ZFN modified T-cells)
Study NCT02225665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: - IV cyclophosphamide 1 g/m2 two days prior to the first SB-728mR-T infusion
Study NCT02608970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986177
Study NCT02608970 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Study NCT03582761 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EV71 vaccine
Description: EV71 vaccine of 320U /0.5ml will be given to 40000 children aged 6-35 months old on day0,28
Study NCT00399971 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ex Vivo Immunotherapy
Description: Allogeneic and autologous ex vivo activated immune cells are given intravenously at least once a week
Study NCT00399971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ex vivo immunotherapy
Description: i.v. infusions, once a week, at least 6 to 12 months
Study NCT01478282 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivaroxaban
Description: 20 mg/day, oral administration maintained for 5 days
Study NCT01478282 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dabigatran
Description: 150 mg/12 hours, administered orally, treatment maintained for 5 days
Study NCT00831636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-4055
Description: D1-5 and D8(+2)-12(+2) q4w
Study NCT00831636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-4055
Description: IV administration day 1-5 and day 8-12 in a 4 week schedule
Study NCT03915665 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine
Description: Chlorhexidine gel 1% one single application after mechanical biofilm removal through manual instruments
Study NCT03915665 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Air-powder
Description: Erythritol powder using air-powder device
Study NCT01147978 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: End of ICU stay conference
Description: Conference with patient and proxies, senior physician and nurse regarding the ICU stay and the orientation of the patient
Study NCT01189500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: Period 1-Tamoxifen 40mg on study day 1.
Study NCT01189500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen and Desvenlafaxine Succinate Sustained Release
Description: Period 2-Desvenlafaxine SR 100mg on days 1-28 with coadministration of Tamoxifen 40mg on day 7.
Study NCT01774825 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: IQP-CL-101
Description: 2 softgels twice a day
Study NCT01774825 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 softgels twice a day
Study NCT05515016 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: chin enhancement with a fatty flap sculpted from the double chin
Description: Under general anesthesia, an incision was made behind the submental crease followed by the excision of the skin excess. The preplatysmal fatty compartment was individualized through a subcutaneous dissection. Then, the lower part of the preplatysmal fat was cut to start its separation from the platysma muscle, thus obtaining a real vascularized fatty flap. This flap could be folded on itself, then easily turned over to be fixed on the muscular layer of the chin.
Study NCT04919941 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A Guide to Conservative Care
Description: The intervention is receipt of a patient decision aid on conservative care, entitled A Guide to Conservative Care. This is 12-page printed handout that provides an overview of conservative care. Participants assigned to the intervention group are mailed a copy of the Guide after their initial baseline visit (T1). Participants keep the Guide throughout the duration of the study.
Study NCT02596321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitizax
Description: Allergen extract
Study NCT02596321 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet
Study NCT01071447 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nurse-led clinic vs rheumatologist-led clinic
Description: The subjects are seeing a rheumatology nurse (experimental arm)instead of a rheumatologist (active comparator arm) after six months. Subjects in both arms are seeing a rheumatologist after 12 months and have the possibility to contact the rheumatology nurse.
Study NCT01071447 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nurse-led clinic vs rheumatologist-led clinic
Description: The subjects are seeing a rheumatology nurse (experimental arm)instead of a rheumatologist (active comparator arm) after six months. Subjects in both arms are seeing a rheumatologist after 12 months and have the possibility to contact the rheumatology nurse.
Study NCT03099122 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rabbit Anti-thymocyte Immunoglobulin
Description: Pharmaceutical form: creamy-white powder~Route of administration: intravenous
Study NCT03099122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Pharmaceutical form: tablet~Route of administration: oral
Study NCT03099122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Pharmaceutical form: powder~Route of administration: intravenous
Study NCT03099122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: Pharmaceutical form: capsule~Route of administration: oral
Study NCT03099122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Na
Description: Pharmaceutical form: capsule~Route of administration: oral
Study NCT03099122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Pharmaceutical form: tablet~Route of administration: oral
Study NCT01482130 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Heavy, explosive strength training
Description: All participants of the training group will pursue a 12 weeks of heavy, explosive strength training, 3 sessions a week for a total of 36 sessions. The training session will include one squat exercise only, which allows muscle contraction of the quadriceps from a 90° bend at the knees to straight legs.
Study NCT01482130 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: recommendations
Description: The control group will be encouraged to follow a training program according to recommended exercise guidelines:~* Weight bearing activities (walking, jogging or strength training)~* 30 - 60 minutes, 3 - 5 times each week~* A total of 2 - 3 hours each week should be achieved
Study NCT05321329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine is a deoxycytidine derivative and fluorouracil PRODRUG that is used as an ANTINEOPLASTIC ANTIMETABOLITE in the treatment of COLON CANCER; BREAST CANCER and GASTRIC CANCER.Capecitabine is a Nucleoside Metabolic Inhibitor. The mechanism of action of capecitabine is as a Nucleic Acid Synthesis Inhibitor.
Study NCT02742441 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Foam
Description: Topical Foam containing no active drug
Study NCT01612676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FE 202158
Study NCT02169011 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Latissimus Dorsi Flap Reconstruction
Description: Delayed, unilateral breast reconstruction with the LD-flap. The reconstruction will be performed in a standard fashion as specified in the protocol. Implants should be used when required to gain sufficient volume of the breast.
Study NCT02169011 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TAP Flap Reconstruction
Description: Delayed, unilateral breast reconstruction with the TAP-flap. The reconstruction will be performed as specified in the protocol and when implants are required to gain sufficient volume they should be combined with an acellular dermal matrix.
Study NCT02307630 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 124I-Humanized 3F8
Study NCT05551468 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: StayFine guided app-based personalised intervention modules
Description: Participants work on guided app-based personalised intervention modules in the StayFine app over the course of three months. The modules are selected by the participant based on shared decision making and a personalized advice. The intervention is based on Preventive Cognitive Therapy (PCT) with elements of Cognitive Behavioral Therapy (CBT) and Positive Psychology. Modules are: psycho education (mandatory), cognitive restructuring (mandatory), positive affect, behavioral activation, exposure, wellness, sleep and a relapse prevention plan (mandatory).
Study NCT05551468 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: StayFine app-based monitoring
Description: Monitoring six times per day for two weeks in the StayFine app.
Study NCT05551468 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: StayFine app-based monitoring
Description: Monitoring six times per day for two weeks in the StayFine app.
Study NCT03976297 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Tower
Description: A workstation and software tool that extracts medical data from Mayo's data mart and electronic health record, and processes it through a prediction model that determines whether a patient is suited for a palliative care consult.
Study NCT03827590 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator Control 1
Description: three times a day for five days
Study NCT03827590 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator Control 2
Description: three times a day for five days
Study NCT03827590 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: three times a day for five days
Study NCT04552223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 480mg administered intravenously on Day 1 of each 4 week cycle.
Study NCT04552223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relatlimab
Description: Relatlimab 160 mg administered intravenously on Day 1 of each 4 week cycle.
Study NCT03407768 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Individualized interventions
Description: A participant will be able to select one or more (or no intervention) based on her preferences.~Individualized exercise program Yoga and mindfulness Massage therapy Acupuncture Others: Women who are not interested in any above intervention but like to explore other interventions will be offered material pertinent to their choice of complimentary techniques.
Study NCT04571814 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psycho-social, computerized intervention targeting error sensitivity
Description: A psycho-social, computerized intervention for parents and children targeting error sensitivity. This intervention will be based on the constructs in the Child Error Sensitivity Index, as well as other constructs, that relate to the error-related negativity - for example, perfectionism, fear of evaluation from others, and over-valuation of the negative consequences of errors. The parent version of the intervention will include these same basic concepts, but will also target parenting style and provide psychoeducation on the negative impact of over-reacting to children's mistakes.~The parent version will also include examples of how to model appropriate reactivity to mistakes, and provide video vignettes and examples of both critical and adaptive parenting reactions to mistakes.
Study NCT04571814 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psycho-social, computerized intervention targeting error sensitivity
Description: A psycho-social, computerized intervention for parents and children targeting error sensitivity. This intervention will be based on the constructs in the Child Error Sensitivity Index, as well as other constructs, that relate to the error-related negativity - for example, perfectionism, fear of evaluation from others, and over-valuation of the negative consequences of errors. The parent version of the intervention will include these same basic concepts, but will also target parenting style and provide psychoeducation on the negative impact of over-reacting to children's mistakes.~The parent version will also include examples of how to model appropriate reactivity to mistakes, and provide video vignettes and examples of both critical and adaptive parenting reactions to mistakes.
Study NCT02467400 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atenolol
Description: beta blocker
Study NCT02467400 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebivolol
Description: beta blocker
Study NCT02467400 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol
Description: beta blocker